Solid Biosciences to Participate at Upcoming Investor Conferences
20 sept. 2021 16h01 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021
24 août 2021 08h00 HE
|
Solid Biosciences Inc.
- Chief Operating Officer to discuss company’s advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development - CAMBRIDGE, Mass., Aug. 24, 2021 (GLOBE NEWSWIRE)...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance
19 août 2021 08h05 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance
19 août 2021 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results
16 août 2021 16h11 HE
|
Solid Biosciences Inc.
- Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development activities continue for pipeline initiatives SGT-003 and Ultragenyx...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development
02 juil. 2021 08h00 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy
01 juil. 2021 08h00 HE
|
Solid Biosciences Inc.
-Additional expertise expected to support attainment of key corporate goals- CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company...
Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer
07 juin 2021 07h35 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer
07 juin 2021 07h30 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference
26 mai 2021 07h30 HE
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...